Best Lisocabtagene Maraleucel (Breyanzi) Medicine in India

Lisocabtagene Maraleucel (Breyanzi) is a personalized CAR T-cell therapy used to treat certain types of relapsed or refractory B-cell lymphomas and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in eligible adults. It uses genetically modified T cells to recognize and attack cancer cells, helping the immune system destroy abnormal B cells and control disease progression.

Lisocabtagene Maraleucel (Breyanzi) is administered as a single intravenous infusion by a qualified healthcare professional after the patient's T cells have been collected, modified, and prepared for treatment. Lymphodepleting chemotherapy is generally given before the infusion. Close medical monitoring is required after treatment to detect and manage serious reactions.

Common side effects of Lisocabtagene Maraleucel (Breyanzi) may include cytokine release syndrome, fatigue, fever, headache, low blood cell counts, nausea, diarrhea, swelling, and infections. Serious side effects may include cytokine release syndrome and neurologic toxicities. Inform your doctor immediately if you develop fever, chills, confusion, difficulty speaking, severe weakness, breathing difficulties, or other concerning symptoms.

Treatment of Relapsed or Refractory B-Cell Cancers

Lisocabtagene Maraleucel (Breyanzi) is used to treat certain relapsed or refractory B-cell lymphomas and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in eligible adults. It uses genetically modified T cells to recognize and attack abnormal B cells, helping to reduce cancer-cell growth and control disease progression.

Some side effects of Lisocabtagene Maraleucel (Breyanzi) may improve as the body adjusts to the treatment. Consult your doctor if any side effect persists, becomes severe, or causes concern.

Common Side Effects of Lisocabtagene Maraleucel (Breyanzi)

Lisocabtagene Maraleucel (Breyanzi) is given as a single intravenous infusion by a qualified healthcare professional. Before treatment, the patient's T cells are collected and genetically modified to recognize cancer cells. Lymphodepleting chemotherapy is usually given before the infusion. Close monitoring is required after treatment to identify and manage cytokine release syndrome and neurological reactions.

Lisocabtagene Maraleucel (Breyanzi) is a CD19-directed CAR T-cell therapy. The patient's T cells are genetically modified to produce a chimeric antigen receptor (CAR) that recognizes CD19, a protein found on many B cells and B-cell cancer cells. These modified T cells bind to CD19-positive cancer cells and activate an immune response that helps destroy them.

• Store and transport Breyanzi frozen in the vapor phase of liquid nitrogen at or below −130°C.
• Keep the product frozen until the patient is ready for treatment.
• After thawing, do not refreeze the product and administer it as soon as possible.
• If necessary, the thawed product may remain at room temperature (15°C to 25°C) for no more than 2 hours before administration.

Alcohol CONSULT YOUR DOCTOR

Avoid alcohol during treatment and recovery, as it may worsen dizziness, fatigue, or other side effects. Follow your doctor's advice.

Pregnancy CONSULT YOUR DOCTOR

Lisocabtagene Maraleucel may pose risks to an unborn baby. Women who can become pregnant should discuss effective contraception with their doctor before and after treatment.

Breastfeeding CONSULT YOUR DOCTOR

Do not breastfeed during treatment unless your doctor advises otherwise, as the effects on a breastfed child are not fully known.

Driving CONSULT YOUR DOCTOR

Do not drive or operate machinery until your doctor confirms it is safe, as treatment may cause dizziness, confusion, or neurological effects.

Kidney CAUTION

Inform your doctor if you have kidney problems. Your healthcare team may monitor kidney function and provide appropriate medical care.

Liver CAUTION

Tell your doctor about any liver condition. Liver function may be monitored during treatment, and report yellowing of the skin or eyes, dark urine, or unusual tiredness promptly.

• Attend all scheduled appointments and follow your healthcare team's instructions before and after Breyanzi treatment.
• Report fever, chills, low blood pressure, breathing difficulties, or rapid heartbeat immediately.
• Seek urgent medical attention for confusion, severe headache, difficulty speaking, seizures, or unusual weakness.
• Avoid driving or operating machinery until your doctor confirms it is safe after treatment.
• Stay in close contact with your healthcare team and attend regular follow-up visits to monitor your recovery and treatment response.
• Read More About - Lisocabtagene Maraleucel (Breyanzi) from Pharma Five.

Pharma Five, may help patients with the import of Lisocabtagene Maraleucel (Breyanzi) in small quantities for personal medical use. For this purpose, the applicant must provide an application in Form 12A along with a prescription issued by a Registered Medical Practitioner (RMP).

Pharma Five provides professional assistance to patients seeking access to Lisocabtagene Maraleucel (Breyanzi), facilitating specialized pharmaceutical requirements through appropriate import-related services. Pharma Five provides extensive pharmaceutical service coverage across India, serving patients and healthcare requirements in prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.